Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (KCT0012606) titled 'Phase II study of lenvatinib in patients with advanced parathyroid carcinoma(ALPS)' on Sept. 10.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Yonsei University Health System, Severance Hospital
Condition:
Neoplasms
Intervention:
Drug : This clinical trial evaluates the efficacy and safety of lenvatinib monotherapy in patients with advanced or metastatic parathyroid cancer. Lenvatinib will be administered orally at a dose of 24 mg once daily, with each cycle consisting of 3 wee...